Literature DB >> 2415603

Mycobacterium leprae antigens involved in human immune responses. I. Identification of four antigens by monoclonal antibodies.

W J Britton, L Hellqvist, A Basten, R L Raison.   

Abstract

Four distinct antigens were identified in soluble sonicates of Mycobacterium leprae by using a panel of 11 monoclonal antibodies. Cross-reactivity studies with other mycobacterial species were conducted by using ELISA and immunoblot assays, and demonstrated that determinants on two of the antigens were present in many mycobacteria, whereas the other two were limited in distribution. Competitive inhibition experiments with radiolabeled monoclonal antibodies showed cross-inhibition between antibodies identifying two of the four antigenic bands. These two bands, of Mr 4.5 to 6 KD and 30 to 40 KD, were resistant to protease treatment after immunoblotting. In contrast, the two other bands of 16 and 70 KD were protease-sensitive. Although all four bands reacted with some human lepromatous leprosy sera in immunoblots, the 4.5 to 6 KD and 30 to 40 KD bands were most prominent. Lepromatous leprosy sera also inhibited the binding of radiolabeled monoclonal antibodies to each of the four antigens, with the mean titer causing 50% inhibition being higher for antibodies reacting with the 4.5 to 6 KD and 30 to 40 KD bands. These findings indicated that all four antigens were involved in the human B cell response to M. leprae.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2415603

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  38 in total

1.  Human T-cell clones to the 70-kilodalton heat shock protein of Mycobacterium leprae define mycobacterium-specific epitopes rather than shared epitopes.

Authors:  E Adams; A Basten; S Rodda; W J Britton
Journal:  Infect Immun       Date:  1997-03       Impact factor: 3.441

2.  Screening of a recombinant mycobacterial DNA library with polyclonal antiserum and molecular weight analysis of expressed antigens.

Authors:  D B Young; L Kent; R A Young
Journal:  Infect Immun       Date:  1987-06       Impact factor: 3.441

3.  Isolation and restriction site maps of the genes encoding five Mycobacterium tuberculosis proteins.

Authors:  T M Shinnick; C Krat; S Schadow
Journal:  Infect Immun       Date:  1987-07       Impact factor: 3.441

4.  T cell reactivity to the purified mycobacterial antigens p65 and p70 in leprosy patients and their household contacts.

Authors:  E Adams; R J Garsia; L Hellqvist; P Holt; A Basten
Journal:  Clin Exp Immunol       Date:  1990-05       Impact factor: 4.330

Review 5.  Immunological study of the defined constituents of mycobacteria.

Authors:  J Ivanyi; K Sharp; P Jackett; G Bothamley
Journal:  Springer Semin Immunopathol       Date:  1988

6.  Inhibition of human lymphoproliferative responses by mycobacterial phenolic glycolipids.

Authors:  J J Fournie; E Adams; R J Mullins; A Basten
Journal:  Infect Immun       Date:  1989-11       Impact factor: 3.441

7.  The variable C-terminal region of the Mycobacterium leprae 70-kilodalton heat shock protein is the target for humoral immune responses.

Authors:  M P Davenport; K R McKenzie; A Basten; W J Britton
Journal:  Infect Immun       Date:  1992-03       Impact factor: 3.441

8.  Serodiagnosis of leprosy: relationships between antibodies to Mycobacterium leprae phenolic glycolipid I and protein antigens.

Authors:  W R Levis; H C Meeker; G B Schuller-Levis; T P Gillis; L J Marino; J Zabriskie
Journal:  J Clin Microbiol       Date:  1986-12       Impact factor: 5.948

9.  Cellular immune responses of leprosy contacts to fractionated Mycobacterium leprae antigens.

Authors:  S P Lee; N G Stoker; K A Grant; Z T Handzel; R Hussain; K P McAdam; H M Dockrell
Journal:  Infect Immun       Date:  1989-08       Impact factor: 3.441

10.  Identification of human T cell epitopes in the Mycobacterium leprae heat shock protein 70-kD antigen.

Authors:  E Adams; W J Britton; A Morgan; A L Goodsall; A Basten
Journal:  Clin Exp Immunol       Date:  1993-12       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.